Nektar Therapeutics (NKTR) Operating Leases (2019 - 2026)

Nektar Therapeutics' Operating Leases history runs 8 years deep, the most recent figure standing at $60.6 million for Q1 2026.

• In Q1 2026, Operating Leases fell 22.76% year-over-year to $60.6 million; the TTM figure through Mar 2026 stood at $60.6 million (down 22.76% YoY), while the FY2025 annual figure was $65.3 million, down 21.09% from the prior year.
• Operating Leases was $60.6 million for Q1 2026 at Nektar Therapeutics, down from $65.3 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $122.6 million in Q1 2022 to a low of $60.6 million in Q1 2026.
• Historically, Operating Leases has averaged $93.5 million across 5 years, with a median of $94.7 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Operating Leases fell 8.86% in 2022, then fell 22.76% in 2026.
• A 5-year view of Operating Leases shows it stood at $112.8 million in 2022, then fell by 12.68% to $98.5 million in 2023, then retreated by 16.06% to $82.7 million in 2024, then declined by 21.09% to $65.3 million in 2025, then declined by 7.09% to $60.6 million in 2026.
• The last three Operating Leases figures came in at $60.6 million (Q1 2026), $65.3 million (Q4 2025), and $69.7 million (Q3 2025), per Business Quant data.